Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 70

1.

Salvage therapy for refractory hemophagocytic lymphohistiocytosis: A review of the published experience.

Marsh RA, Jordan MB, Talano JA, Nichols KE, Kumar A, Naqvi A, Vaiselbuh SR; Histiocyte Society Salvage Therapy Working Group..

Pediatr Blood Cancer. 2016 Oct 27. doi: 10.1002/pbc.26308. [Epub ahead of print] Review.

PMID:
27786410
2.

A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.

Khandelwal P, Emoto C, Fukuda T, Vinks AA, Neumeier L, Dandoy CE, El-Bietar J, Chandra S, Davies SM, Bleesing JJ, Jordan MB, Mehta PA, Jodele S, Grimley MS, Kumar A, Myers KC, Marsh RA.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2220-2225. doi: 10.1016/j.bbmt.2016.09.016.

PMID:
27664325
3.

Outcome of patients with NEMO deficiency following allogeneic hematopoietic cell transplant.

Chandrakasan S, Marsh RA, Uzel G, Holland SM, Shah KN, Bleesing J.

J Allergy Clin Immunol. 2016 Oct 12. pii: S0091-6749(16)31123-X. doi: 10.1016/j.jaci.2016.08.039. [Epub ahead of print] No abstract available.

PMID:
27744027
4.
5.

A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses.

Khandelwal P, Fukuda T, Mizuno K, Teusink-Cross A, Mehta PA, Marsh RA, Kashuba AD, Vinks AA, Davies SM.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1829-35. doi: 10.1016/j.bbmt.2016.08.001.

PMID:
27498124
6.

A Reduced-Intensity Conditioning Regimen for Patients with Dyskeratosis Congenita Undergoing Hematopoietic Stem Cell Transplantation.

Nelson AS, Marsh RA, Myers KC, Davies SM, Jodele S, O'Brien TA, Mehta PA.

Biol Blood Marrow Transplant. 2016 May;22(5):884-8. doi: 10.1016/j.bbmt.2016.01.026.

PMID:
26845033
7.

Cytokine Profile of Engraftment Syndrome in Pediatric Hematopoietic Stem Cell Transplant Recipients.

Khandelwal P, Mellor-Heineke S, Rehman N, Lane A, Smiley K, Villanueva J, Marsh RA, Grimley MS, Davies SM, Filipovich AH.

Biol Blood Marrow Transplant. 2016 Apr;22(4):690-7. doi: 10.1016/j.bbmt.2015.12.016.

PMID:
26740373
8.

Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT.

Marsh RA, Lane A, Mehta PA, Neumeier L, Jodele S, Davies SM, Filipovich AH.

Blood. 2016 Jan 28;127(4):503-12. doi: 10.1182/blood-2015-07-659672.

PMID:
26644451
9.

Accuracy of flow cytometric perforin screening for detecting patients with FHL due to PRF1 mutations.

Abdalgani M, Filipovich AH, Choo S, Zhang K, Gifford C, Villanueva J, Bleesing JJ, Marsh RA.

Blood. 2015 Oct 8;126(15):1858-60. doi: 10.1182/blood-2015-06-648659. No abstract available.

10.

Peripheral Blood CD38 Bright CD8+ Effector Memory T Cells Predict Acute Graft-versus-Host Disease.

Khandelwal P, Lane A, Chaturvedi V, Owsley E, Davies SM, Marmer D, Filipovich AH, Jordan MB, Marsh RA.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1215-22. doi: 10.1016/j.bbmt.2015.04.010.

11.

Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.

Marsh RA, Rao MB, Gefen A, Bellman D, Mehta PA, Khandelwal P, Chandra S, Jodele S, Myers KC, Grimley M, Dandoy C, El-Bietar J, Kumar AR, Leemhuis T, Zhang K, Bleesing JJ, Jordan MB, Filipovich AH, Davies SM.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1460-70. doi: 10.1016/j.bbmt.2015.04.009.

12.

Hemophagocytic lymphohistiocytosis in a female patient due to a heterozygous XIAP mutation and skewed X chromosome inactivation.

Holle JR, Marsh RA, Holdcroft AM, Davies SM, Wang L, Zhang K, Jordan MB.

Pediatr Blood Cancer. 2015 Jul;62(7):1288-90. doi: 10.1002/pbc.25483.

PMID:
25801017
13.

Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases.

Haines HL, Bleesing JJ, Davies SM, Hornung L, Jordan MB, Marsh RA, Filipovich AH.

Biol Blood Marrow Transplant. 2015 Feb;21(2):288-92. doi: 10.1016/j.bbmt.2014.10.010.

14.

Fauna in decline--response.

Withey L, Seto K, McCauley DJ, Fiorella KJ, Marsh RA, Abrahms B, Nuñez TA, Golden CD, Brashares JS.

Science. 2014 Nov 14;346(6211):819-20. doi: 10.1126/science.346.6211.819-c. No abstract available.

PMID:
25395527
15.

Conservation policy. Wildlife decline and social conflict.

Brashares JS, Abrahms B, Fiorella KJ, Golden CD, Hojnowski CE, Marsh RA, McCauley DJ, Nuñez TA, Seto K, Withey L.

Science. 2014 Jul 25;345(6195):376-8. doi: 10.1126/science.1256734. No abstract available.

PMID:
25061187
16.

Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1.

Marsh RA, Bleesing JJ, Chandrakasan S, Jordan MB, Davies SM, Filipovich AH.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1641-5. doi: 10.1016/j.bbmt.2014.06.003.

17.

Clinical flow cytometric screening of SAP and XIAP expression accurately identifies patients with SH2D1A and XIAP/BIRC4 mutations.

Gifford CE, Weingartner E, Villanueva J, Johnson J, Zhang K, Filipovich AH, Bleesing JJ, Marsh RA.

Cytometry B Clin Cytom. 2014 Jul;86(4):263-71. doi: 10.1002/cyto.b.21166.

18.

Clinical Flow Cytometric Screening of SAP and XIAP Expression Accurately Identifies Patients with SH2D1A and XIAP/BIRC4 Mutations.

Gifford CE, Weingartner E, Villanueva J, Johnson J, Zhang K, Filipovich AH, Bleesing JJ, Marsh RA.

Cytometry B Clin Cytom. 2014 Feb 7. doi: 10.1002/cytob.21166. [Epub ahead of print]

19.

The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.

Khandelwal P, Lawrence J, Filipovich AH, Davies SM, Bleesing JJ, Jordan MB, Mehta P, Jodele S, Grimley MS, Kumar A, Myers K, Marsh RA.

Pediatr Transplant. 2014 Feb;18(1):94-102. doi: 10.1111/petr.12183.

20.

Primary Immune Deficiency Treatment Consortium (PIDTC) report.

Griffith LM, Cowan MJ, Notarangelo LD, Kohn DB, Puck JM, Pai SY, Ballard B, Bauer SC, Bleesing JJ, Boyle M, Brower A, Buckley RH, van der Burg M, Burroughs LM, Candotti F, Cant AJ, Chatila T, Cunningham-Rundles C, Dinauer MC, Dvorak CC, Filipovich AH, Fleisher TA, Bobby Gaspar H, Gungor T, Haddad E, Hovermale E, Huang F, Hurley A, Hurley M, Iyengar S, Kang EM, Logan BR, Long-Boyle JR, Malech HL, McGhee SA, Modell F, Modell V, Ochs HD, O'Reilly RJ, Parkman R, Rawlings DJ, Routes JM, Shearer WT, Small TN, Smith H, Sullivan KE, Szabolcs P, Thrasher A, Torgerson TR, Veys P, Weinberg K, Zuniga-Pflucker JC; workshop participants..

J Allergy Clin Immunol. 2014 Feb;133(2):335-47. doi: 10.1016/j.jaci.2013.07.052.

Items per page

Supplemental Content

Loading ...
Support Center